TL1A

Latest news

Tag

Unveiling the TL1A-LTα1β2/IL-22 Axis: A New Therapeutic Target in Crohn’s Disease with Perianal Fistulising Disease

This study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis in

Sep 19, 2026Sign in to read

Clinical Updates

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite

Aug 26, 2025

Clinical Updates

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.

Aug 2, 2025Sign in to read